FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3012024791> ?p ?o ?g. }

• W3012024791 endingPage "331" @default.
• W3012024791 startingPage "331" @default.
• W3012024791 abstract "Neurofibromatosis Type 1 (NF1)-related Malignant Peripheral Nerve Sheath Tumors (MPNST) are highly resistant sarcomas that account for significant mortality. The mechanisms of therapy resistance are not well-understood in MPNSTs, particularly with respect to kinase inhibition strategies. In this study, we aimed to quantify the impact of both the genomic context and targeted therapy on MPNST resistance using reverse phase phosphoproteome array (RPPA) analysis. We treated tumorgrafts from three genetically engineered mouse models using MET (capmatinib) and MEK (trametinib) inhibitors and doxorubicin, and assessed phosphosignaling at 4 h, 2 days, and 21 days. Baseline kinase signaling in our mouse models recapitulated an MET-addicted state (NF1-MET), P53 mutation (NF1-P53), and HGF overexpression (NF1). Following perturbation with the drug, we observed broad and redundant kinome adaptations that extended well beyond canonical RAS/ERK or PI3K/AKT/mTOR signaling. MET and MEK inhibition were both associated with an initial inflammatory response mediated by kinases in the JAK/STAT pathway and NFkB. Growth signaling predominated at the 2-day and 21-day time points as a result of broad RTK and intracellular kinase activation. Interestingly, AXL and NFkB were strongly activated at the 2-day and 21-day time points, and tightly correlated, regardless of the treatment type or genomic context. The degree of kinome adaptation observed in innately resistant tumors was significantly less than the surviving fractions of responsive tumors that exhibited a latency period before reinitiating growth. Lastly, doxorubicin resistance was associated with kinome adaptations that strongly favored growth and survival signaling. These observations confirm that MPNSTs are capable of profound signaling plasticity in the face of kinase inhibition or DNA damaging agent administration. It is possible that by targeting AXL or NFkB, therapy resistance can be mitigated." @default.
• W3012024791 created "2020-03-23" @default.
• W3012024791 creator A5013167357 @default.
• W3012024791 creator A5023007391 @default.
• W3012024791 creator A5023762376 @default.
• W3012024791 creator A5026553060 @default.
• W3012024791 creator A5028535795 @default.
• W3012024791 creator A5032570245 @default.
• W3012024791 creator A5052431705 @default.
• W3012024791 creator A5066445202 @default.
• W3012024791 creator A5071088611 @default.
• W3012024791 creator A5081701591 @default.
• W3012024791 date "2020-03-20" @default.
• W3012024791 modified "2023-09-23" @default.
• W3012024791 title "Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities" @default.
• W3012024791 cites W1543790510 @default.
• W3012024791 cites W1920165451 @default.
• W3012024791 cites W1964914880 @default.
• W3012024791 cites W1973563587 @default.
• W3012024791 cites W1974290681 @default.
• W3012024791 cites W1977197767 @default.
• W3012024791 cites W1999025555 @default.
• W3012024791 cites W2004338566 @default.
• W3012024791 cites W2014445008 @default.
• W3012024791 cites W2021533022 @default.
• W3012024791 cites W2029695051 @default.
• W3012024791 cites W2035873246 @default.
• W3012024791 cites W2052005627 @default.
• W3012024791 cites W2052705131 @default.
• W3012024791 cites W2053442386 @default.
• W3012024791 cites W2055729102 @default.
• W3012024791 cites W2058659214 @default.
• W3012024791 cites W2105118244 @default.
• W3012024791 cites W2112205322 @default.
• W3012024791 cites W2115424172 @default.
• W3012024791 cites W2121550925 @default.
• W3012024791 cites W2124453937 @default.
• W3012024791 cites W2136390065 @default.
• W3012024791 cites W2142991339 @default.
• W3012024791 cites W2154151857 @default.
• W3012024791 cites W2155927284 @default.
• W3012024791 cites W2158416296 @default.
• W3012024791 cites W2413552560 @default.
• W3012024791 cites W2527955139 @default.
• W3012024791 cites W2537836937 @default.
• W3012024791 cites W2567378356 @default.
• W3012024791 cites W2592127988 @default.
• W3012024791 cites W2594459336 @default.
• W3012024791 cites W2607286302 @default.
• W3012024791 cites W2746563129 @default.
• W3012024791 cites W2761437070 @default.
• W3012024791 cites W2802173235 @default.
• W3012024791 cites W2802470236 @default.
• W3012024791 cites W2884268103 @default.
• W3012024791 cites W2884353594 @default.
• W3012024791 cites W2890317645 @default.
• W3012024791 cites W2902527990 @default.
• W3012024791 cites W2948990828 @default.
• W3012024791 cites W2970127552 @default.
• W3012024791 cites W2990240286 @default.
• W3012024791 cites W2995284805 @default.
• W3012024791 cites W4232218865 @default.
• W3012024791 doi "https://doi.org/10.3390/genes11030331" @default.
• W3012024791 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7141129" @default.
• W3012024791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32245042" @default.
• W3012024791 hasPublicationYear "2020" @default.
• W3012024791 type Work @default.
• W3012024791 sameAs 3012024791 @default.
• W3012024791 citedByCount "8" @default.
• W3012024791 countsByYear W30120247912020 @default.
• W3012024791 countsByYear W30120247912021 @default.
• W3012024791 countsByYear W30120247912022 @default.
• W3012024791 countsByYear W30120247912023 @default.
• W3012024791 crossrefType "journal-article" @default.
• W3012024791 hasAuthorship W3012024791A5013167357 @default.
• W3012024791 hasAuthorship W3012024791A5023007391 @default.
• W3012024791 hasAuthorship W3012024791A5023762376 @default.
• W3012024791 hasAuthorship W3012024791A5026553060 @default.
• W3012024791 hasAuthorship W3012024791A5028535795 @default.
• W3012024791 hasAuthorship W3012024791A5032570245 @default.
• W3012024791 hasAuthorship W3012024791A5052431705 @default.
• W3012024791 hasAuthorship W3012024791A5066445202 @default.
• W3012024791 hasAuthorship W3012024791A5071088611 @default.
• W3012024791 hasAuthorship W3012024791A5081701591 @default.
• W3012024791 hasBestOaLocation W30120247911 @default.
• W3012024791 hasConcept C151730666 @default.
• W3012024791 hasConcept C184235292 @default.
• W3012024791 hasConcept C2778472372 @default.
• W3012024791 hasConcept C2778984943 @default.
• W3012024791 hasConcept C2779343474 @default.
• W3012024791 hasConcept C2781249067 @default.
• W3012024791 hasConcept C502942594 @default.
• W3012024791 hasConcept C54174078 @default.
• W3012024791 hasConcept C54355233 @default.
• W3012024791 hasConcept C57074206 @default.
• W3012024791 hasConcept C62478195 @default.
• W3012024791 hasConcept C71924100 @default.
• W3012024791 hasConcept C75217442 @default.

• next